NUVB
Overvalued by 86.4% based on the discounted cash flow analysis.
Market cap | $833.13 Million |
---|---|
Enterprise Value | $807.00 Million |
Dividend Yield | $0 (0%) |
Earnings per Share | $-2.11 |
Beta | 1.47 |
Outstanding Shares | 336,934,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -1.46 |
---|---|
PEG | -1.33 |
Price to Sales | - |
Price to Book Ratio | 2.1 |
Enterprise Value to Revenue | 332.64 |
Enterprise Value to EBIT | -6 |
Enterprise Value to Net Income | -2 |
Total Debt to Enterprise | 0.01 |
Debt to Equity | 0.02 |
No data
No data
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically ...